Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Verteporfin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Verteporfin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-004978-27 Sponsor Protocol Number: 1-2006 Start Date*: 2007-08-03
    Sponsor Name:Zentralklinikum St. Pölten
    Full Title: Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular Degene...
    Medical condition: The case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne) for the treatment of subfoveal CNV s...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002912-73 Sponsor Protocol Number: AL-JVC-05-01 Start Date*: 2005-08-02
    Sponsor Name:University Hospitals Leuven
    Full Title: An Open Label Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of 15 mg Anecortave Acetate for Depot Suspension Combined with Verteporfin Therapy in Patients with Exudati...
    Medical condition: Age Related Macular Degeneration with Retino-choroidal Anastomosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002977-33 Sponsor Protocol Number: Luc01AKSI Start Date*: 2006-06-22
    Sponsor Name:University Eye Hospital
    Full Title: Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to ag...
    Medical condition: Age related macular degeneration (AMD) is the leading cause of blindness in individuals older than 50 years in the developed world. Eighty to ninety percent of rapid and severe vision loss due to A...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006760-28 Sponsor Protocol Number: 13 Start Date*: 2008-02-21
    Sponsor Name:Ludwig Boltzmann Institut für Retinologie und biomikroskopische Laserchirurgie
    Full Title: Comparision of Ranibizumab (Lucentis) Monotherapy versus Combination of Ranibizumab (Lucentis) with Photodynamic Therapy (Verteporfin) in Patients with Subfoveal Choroidal Neovascularisation due to...
    Medical condition: neovascular Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001200-36 Sponsor Protocol Number: AVA001 Start Date*: 2006-09-18
    Sponsor Name:St. Eriks Eye Hospital [...]
    1. St. Eriks Eye Hospital
    2.
    3. St. Eriks Eye Hospital
    4.
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin) versus verteporfin photodynamic therapy (PDT) in patients with neovascular age-related macular degenera...
    Medical condition: Age-related macular degeneration (AMD) is the leading cause of visual impairment and social blindness in people 60 years or older. Approximately 75% of patients with severe visual loss exhibit ne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001368-20 Sponsor Protocol Number: ECR-AMD-2015-09 Start Date*: 2015-09-01
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research ob Light and Image
    Full Title: A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic The...
    Medical condition: Polypoidal Choroidal Vasculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000776-41 Sponsor Protocol Number: V1.0 Start Date*: 2005-06-22
    Sponsor Name:Department of Ophthalmology
    Full Title: Comparison of reduced fluence versus standard photodynamic therapy (in combination with intravitreal triamcinolone acetonide): A prospective, randomized, comparative study
    Medical condition: Forty patients will be enrolled into two cohorts of 20 patients each. The study population will consist of male and female patients > 50 years of age with subfoveal CNV secondary to AMD.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004292-35 Sponsor Protocol Number: 06NB37 Start Date*: 2007-03-08
    Sponsor Name:Kings College Hospital NHS Foundation Trust
    Full Title: A pillot study to examine the safety and efficacy of intravitreal ranubizimab/dexamethasone administration and oral minocycline in addition to Visudyne (verteporfin) photdynamic therapy for subfove...
    Medical condition: Age related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004367-57 Sponsor Protocol Number: Start Date*: 2008-05-14
    Sponsor Name:Department of Ophthalmology, Medical University of Graz
    Full Title: Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®)
    Medical condition: Subtype of neovascular age-related macular degeneration, so called retinal angiomatous proliferation or RAP.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004464-54 Sponsor Protocol Number: BAY86-5321/16995 Start Date*: 2014-05-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic ...
    Medical condition: Polypoidal Choroidal Vasculopathy (PCV)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021923-29 Sponsor Protocol Number: 10032011 Start Date*: 2011-08-11
    Sponsor Name:Universitätsklinik für Augenheilkunden und Optometrie, Medizinische Universität Wien
    Full Title: Management of recurrent or persistent choroidal neovascularization secondary to age-related macular degeneration A prospective, randomized, clinical study
    Medical condition: Neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004172-12 Sponsor Protocol Number: CBPD952A2309 Start Date*: 2007-01-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Luc...
    Medical condition: Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-019714-24 Sponsor Protocol Number: 10.002 Start Date*: 2010-09-02
    Sponsor Name:Research & Development Department
    Full Title: A phase II, open label, single site light dose escalation trial of single dose Verteporfin Photodynamic Therapy (PDT) in primary soft tissue sarcoma
    Medical condition: Primary soft tissue sarcoma in the upper and lower limbs of adults.
    Disease: Version SOC Term Classification Code Term Level
    13 10061271 Malignant soft tissue neoplasm LLT
    13 10039491 Sarcoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-000544-13 Sponsor Protocol Number: HCSCOM-miopía2 Start Date*: 2008-04-15
    Sponsor Name:Departamento de Oftalmología. Hospital Clínico San Carlos
    Full Title: Estudio sobre la eficacia y la seguridad del tratamiento combinado con ranibizumab (Lucentis®) y terapia fotodinámica con verteporfin (Visudyne®) versus monoterapia con ranibizumab (Lucentis®) en l...
    Medical condition: Pacientes con neovascularización coroidea secundaria a miopía magna
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005290-30 Sponsor Protocol Number: TCA-05-01 Start Date*: 2006-10-18
    Sponsor Name:Department of Ophthalmology, Semmelweis University
    Full Title: A Non- randomized, Single-Center, Open Label Case Series Study of Intravitreal Triamcinolone Acetate Injections (IVTA) Used as Adjunctive to Verteporfin Photodynamic Therapy (PDT) in the Treatment ...
    Medical condition: Age- related macular degeneration with predominantly classic subfoveal choroidal neovascularisation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10015902 Exudative senile macular degeneration of retina LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002466-11 Sponsor Protocol Number: version125/05/05 Start Date*: 2006-01-03
    Sponsor Name:King's College Hospital
    Full Title: A Pilot Study to Examine the Safety and Efficacy of Posterior Juxtascleral Triamcinolone acetonide administration, in addition to Visudyne photoynamic therapy for predominantly Classic Choroidal N...
    Medical condition: Classic or predominantly classic age related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004097-28 Sponsor Protocol Number: BRD/06/078 Start Date*: 2007-01-12
    Sponsor Name:University College Hospitals NHS Foundation Trust/ University College London
    Full Title: A Phase 1 Trial of Verteporfin Photodynamic Therapy in Unresectable Pancreatic Carcinoma (VERTPAC-01 study)
    Medical condition: Unresectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021662-30 Sponsor Protocol Number: CRFB002F2301 Start Date*: 2010-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PD...
    Medical condition: visual impairment due to choroidal neovascularization secondary to pathologic myopia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036803 Progressive high (degenerative) myopia LLT
    12.1 10060837 Choroidal neovascularization LLT
    12.1 10047571 Visual impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) ES (Completed) IT (Completed) AT (Completed) SK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001386-42 Sponsor Protocol Number: REC no:06/Q0403/25 Start Date*: 2006-07-06
    Sponsor Name:Imperial College
    Full Title: The timing of intra-vitreal (4mg) triamcinolone acetonide, in addition to verteporfin photodynamic therapy for choroidal neovascularisation, in age-related macular degeneration: a prospective rando...
    Medical condition: Submacular choroidal neovascularisation in Age-related Macular Degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003976-36 Sponsor Protocol Number: CBPD952ABE02 Start Date*: 2006-09-01
    Sponsor Name:Professor Anita Leys - Dienst Oftalmologie UZ St. Rafaël
    Full Title: An academic monocenter study assessing the safety and efficacy of Lucentis (ranizumab 0.3 mg) administered in conjunction with photodynamic therapy with Visudyne in patients with occult or predomi...
    Medical condition: Male and female patients ≥50 years of age with subfoveal choroidal neovascularisation lesions secondary to age related macular degeneration, either predominantly classic or occult with no classic c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 08:24:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA